Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections-Reference-Cited by-同舟云学术

Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Abutaleb Nader S.¹,Seleem Mohamed N.¹²

Affiliation:

1. Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA

2. Purdue Institute of Inflammation, Immunology, and Infectious Disease, West Lafayette, Indiana, USA

Abstract

Clostridioides difficile , the leading cause of nosocomial infections, is an urgent health threat worldwide. The increased incidence and severity of disease, the high recurrence rates, and the dearth of effective anticlostridial drugs have created an urgent need for new therapeutic agents. In an effort to discover new drugs for the treatment of Clostridioides difficile infections (CDIs), we investigated a panel of FDA-approved antiparasitic drugs against C. difficile and identified diiodohydroxyquinoline (DIHQ), an FDA-approved oral antiamoebic drug.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02115-19

Reference55 articles.

1. Epidemiology and control of Clostridium difficile infections in healthcare settings

2. Burden of Clostridium difficile on the Healthcare System

3. Vital signs: preventing Clostridium difficile infections;Centers for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,2012